Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAN-01
- Development stage
- Preclinical
- Lead developer
- Q BioMed
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
MAN-01 is an investigational small molecule drug candidate developed for the treatment of intraocular eye pressure, specifically targeting Schlemm's Canal in the eye. It is positioned as a first-in-class therapy for conditions such as glaucoma by modulating outflow through this critical anatomical structure[1]. Additionally, under the name "Cannabinoid-MAN01," it has been described as a chemical drug with potential applications in central nervous system diseases. The compound was initially developed by TRx Biosciences Limited and further advanced by Mandara Sciences LLC (Mandara Pharma)[2]. Its mechanism of action and specific molecular targets have not been publicly disclosed.
- Other names
- Cannabinoid-MAN01Cannabinoid-MAN-01Cannabinoid-MAN 01
02
Targets
TEK (Tie2)
Beyond the preview
Go deeper on MAN-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAN-01.